Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02314156 · ClinicalTrials.gov registry record · Phase 2
Transdermal or Oral Telapristone Acetate in Treating Patients Undergoing Mastectomy
A Phase 2 study, sponsored by Northwestern University.
- Completed
- Registry status
- Phase 2
- Development phase
- 67
- Enrollment target
NCT02314156 is a Phase 2 study that has completed, run by Northwestern University. The registered enrollment target is 67 participants.
The verdict
NCT02314156, a Phase 2 study, has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 67 participants
- Enrollment target
Study Summary
This randomized trial studies transdermal or oral telapristone acetate in treating patients undergoing surgery to remove the breast (mastectomy). Telapristone acetate may help prevent breast cancer from forming in premenopausal women. Giving telapristone acetate transdermally may be safer and have fewer side effects than oral administration.
Interventions
- OTHER Placebo
- OTHER Laboratory Biomarker Analysis
- DRUG Telapristone Acetate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2015-10 |
| Est. Completion | 2021-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02314156
The ClinicalTrials.gov registry entry for NCT02314156 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 67 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02314156 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02314156 about?
NCT02314156 is a clinical study titled "Transdermal or Oral Telapristone Acetate in Treating Patients Undergoing Mastectomy". This randomized trial studies transdermal or oral telapristone acetate in treating patients undergoing surgery to remove the breast (mastectomy). Telapristone acetate may help prevent breast cancer from forming in premenopausal women. Giving telapristone acetate transdermally may be safer and have f...
What is the current status of trial NCT02314156?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 67 participants. The study started on 2015-10. Estimated completion is 2021-05.
What interventions are being tested in trial NCT02314156?
The interventions under investigation include: Placebo (OTHER), Laboratory Biomarker Analysis (OTHER), Telapristone Acetate (DRUG).
Who is sponsoring clinical trial NCT02314156?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.